Patents by Inventor Andreas Menrad

Andreas Menrad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHABETATCR ANTIBODY
    Publication number: 20220153841
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: October 26, 2021
    Publication date: May 19, 2022
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • METHODS FOR ENHANCING IMMUNOSUPPRESSIVE THERAPY BY MULTIPLE ADMINISTRATION OF ALPHA BETA TCR-BINDING POLYPEPTIDE
    Publication number: 20220098299
    Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? T cells in the subject are provided.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 31, 2022
    Inventors: Gregor Blank, Rubert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
  • Anti-??TCR antibody
    Patent number: 11186638
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 30, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Methods for enhancing immunosuppressive therapy by multiple administration of ??TCR-binding polypeptide
    Patent number: 11142575
    Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? cells in the subject are provided.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: October 12, 2021
    Assignees: GENZYME CORPORATION, EBERHARD KARLS UNIVERSITÄT TÜBINGEN
    Inventors: Gregor Blank, Rupert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
  • ANTI-ALPHABETATCR ANTIBODY
    Publication number: 20180237522
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: January 10, 2018
    Publication date: August 23, 2018
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Anti-??TCR antibody
    Patent number: 10017573
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 10, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • METHODS FOR ENHANCING IMMUNOSUPPRESSIVE THERAPY BY MULTIPLE ADMINISTRATION OF ALPHA BETA TCR-BINDING POLYPEPTIDE
    Publication number: 20160244523
    Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? cells in the subject are provided.
    Type: Application
    Filed: October 30, 2014
    Publication date: August 25, 2016
    Inventors: Gregor Blank, Rupert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
  • Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
    Patent number: 9289470
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 22, 2016
    Assignee: PHILOGEN S.P.A.
    Inventors: Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann
  • ANTI ALPHABETATCR ANTIBODY
    Publication number: 20150099861
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: September 12, 2012
    Publication date: April 9, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART
    Publication number: 20140294723
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Applicant: PHILOGEN S.P.A.
    Inventors: Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann
  • Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
    Patent number: 8796426
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: August 5, 2014
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • Aza- and polyazanthranyl amides and their use as medicaments
    Publication number: 20110071165
    Abstract: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.
    Type: Application
    Filed: November 24, 2010
    Publication date: March 24, 2011
    Applicant: NOVARTIS AG
    Inventors: Dieter SEIDELMANN, Martin KRÜGER, Orlin PETROV, Andreas HUTH, Karl-Heinz THIERAUCH, Andreas MENRAD, Martin HABEREY
  • Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine
    Patent number: 7851599
    Abstract: The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognizing the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: December 14, 2010
    Assignee: Philogen S.p.A.
    Inventors: Andreas Menrad, Hans Dietrich Menssen, Karola Wagner
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND /OR THEIR CANCEROUS COUNTERPART
    Publication number: 20100310454
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: November 8, 2008
    Publication date: December 9, 2010
    Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
    Patent number: 7785591
    Abstract: The invention relates to recombinant polypeptides, in particular antibodies or antibody fragments that bind Ed-B-isoforms of fibronectin and can block their function. In addition, the diagnostic and pharmaceutical application of the polypeptides according to the invention is disclosed.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: August 31, 2010
    Assignee: MorphoSys AG
    Inventors: Andreas Menrad, Josef Prassler, Armin Weidmann
  • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
    Patent number: 7615565
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: November 10, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuat Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART
    Publication number: 20090202473
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: November 13, 2008
    Publication date: August 13, 2009
    Inventors: Dario NERI, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • ANTI EPHB4 ANTIBODIES AND ANTIBODY FRAGMENTS
    Publication number: 20090137002
    Abstract: The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy.
    Type: Application
    Filed: July 30, 2008
    Publication date: May 28, 2009
    Inventors: Heike PETRUL, Andreas Menrad, Jorg Willuda, Dieter Zopf, Jens Glienke, Josef Prassler, Andreas Popp, Stefan Steidl, Catrin Pracht
  • USE OF A FUSION PROTEIN TARGETING THE ED-B FIBRONECTIN DOMAIN FOR TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20090117073
    Abstract: The present invention relates to the use of a fusion protein comprising an antibody part which specifically recognises ED-B fibronectin, an effector part and optionally one or more fusion protein linker(s) and/or antibody linker(s), for the manufacturing of medicaments for the treatment and prevention of atherosclerosis
    Type: Application
    Filed: October 30, 2007
    Publication date: May 7, 2009
    Inventors: Andreas Menrad, Hans Dietrich Menssen, Kristof Graf
  • Combination of an anti-ED - B fibronectin domain antibody - IL-2 fusion protein and gemcitabine
    Publication number: 20090110660
    Abstract: The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognising the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.
    Type: Application
    Filed: April 4, 2007
    Publication date: April 30, 2009
    Inventors: ANDREAS MENRAD, HANS DIETRICH MENSSEN, KAROLA WAGNER